Journal article
CARESS: The Canadian Registry of Palivizumab
Abstract
BACKGROUND: Palivizumab is indicated for respiratory syncytial virus (RSV) prophylaxis in high-risk children. However, relatively little is known about the current use, compliance, and outcomes associated with this medication.
METHODS: A prospective, observational, registry based on 27 sites, with monthly follow-up of infants at high risk for RSV who received at least 1 dose of palivizumab during the 2005-2009 RSV seasons.
Authors
Mitchell I; Paes BA; Li A; Lanctôt KL
Journal
The Pediatric Infectious Disease Journal, Vol. 30, No. 8, pp. 651–655
Publisher
Wolters Kluwer
Publication Date
August 2011
DOI
10.1097/inf.0b013e31821146f7
ISSN
0891-3668